Application Note

Optimizing Parameters For 10-Day And 20-Day T Cell Expansion In Rocking Bioreactors Using CTS OpTmizer T Cell Expansion SFM

Source: Thermo Fisher Scientific
Cell expansion iStock-1090837544

A surge in the adoptive cell therapy field has increased the demand for improved workflow automation and process control, leading those manufacturing T cell therapies to use rocking bioreactors. The closed design of single-use bioreactors allows for control of optimal environmental conditions such as efficient gas exchange and reduced shear forces on cells. Additionally, these systems can reduce setup time, lower operating costs, and allow the flexibility of a wide range of working volumes. When scaling up a T cell manufacturing process from plates or flasks to a larger bioreactor, the culture medium used cannot be taken for granted.

Herein, we present the results of investigations to optimize the operating parameters for T cell expansion with CTS OpTmizer T Cell Expansion SFM in static and perfusion bioreactor systems. Moreover, we provide data demonstrating that CTS OpTmizer T Cell Expansion SFM supports high T cell growth performance in static bioreactors like the G-Rex™ cell expansion system (Wilson Wolf) and rocking-platform systems like the HyPerforma Rocker Bioreactor and Xuri Cell Expansion System W25. In addition, the combination of CTS OpTmizer T Cell Expansion SFM with the perfusion capabilities of the Xuri Cell Expansion System W25 proved to be well suited to the longer workflows associated with allogeneic therapy production.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma